ArtGen 

a gene therapy startup developing a novel non-viral gene therapy for treatment of vascular diseases

OWNER

Dmitry Krasotkin (See Profile)


Sector

Therapeutics

Stage

Prototyping, preclinical

Country

United States

The disease affects 8.5M+ people in the United States and represents an estimated $4.3B market in the U.S. alone.

ART-101’S MECHANISM OF ACTION AND PLASMID DESIGN IS BASED ON AN APPROVED THERAPEUTIC IN EASTERN EUROPE.

TO DATE, MORE THAN 2,000 PAD PATIENTS HAD BEEN SUCCESSFULLY TREATED WITH NO ADVERSE EFFECTS OR COMPLICATIONS OBSERVED.

This information is confidential, do not share or copy.

You can visit their website or

Download the Pitch Deck
If you want to have more information or you want to review the project, you have to login or register

KEEP REVIEWING

©2023 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

ACEPTAR
Aviso de cookies

Log in with your credentials

or    

Forgot your details?

Create Account

Skip to toolbar